



Market Announcement

29 January 2024

Arovella Therapeutics Limited (ASX: ALA) – Trading Halt

Description

The securities of Arovella Therapeutics Limited ('ALA') will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 31 January 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000

29 January 2024

BY EMAIL to: melissa.kostopoulos@asx.com.au & tradinghaltsmelbourne@asx.com.au

Dear Melissa

REQUEST FOR TRADING HALT

Arovella Therapeutics Limited (ASX: ALA) (the “Company”) requests that a trading halt be granted by the Australian Securities Exchange (“ASX”) with respect to its ordinary shares to apply from the commencement of trading on 29 January 2024 until the commencement of trading on 31 January 2024.

As required by ASX Listing Rule 17.1, the Company provides the following information:

1. The Company requests a trading halt immediately, pending the release of an announcement regarding a licensing agreement.
2. The Company requests that the trading halt remain in place until the earlier of the commencement of trade on 31 January 2024 or the release of an announcement by the Company in respect of the licensing agreement; and
3. The Company is not aware of any reason why the trading halt should not be granted, or any other information necessary to inform the market about the trading halt.

This request has been authorised by the Board of Arovella Therapeutics Limited.

Kind regards



Tim Luscombe
Company Secretary & CFO
Arovella Therapeutics Limited